MedTrace Logo

Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders

NCT04101058 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-10-17

No results posted yet for this study

Summary

Neuromyelitis Optica (NMO)/ Neuromyelitis Optica Spectrum Disorders (NMOSD) is an immune-mediated inflammatory demyelinating disease of the central nervous system mainly involving optic nerve and spinal cord. It is clinically characterized by simultaneous or sequential involvement of the optic nerve and spinal cord, presenting a progressive or remission and relapse course, which can lead to paralysis and blindness.

The objective of this study is to provide evidence regarding treat effects and factors related to prognosis which will help physicians better evaluable risk-benefit in NMOSD management and improve patients' outcome.

Conditions

  • Neuromyelitis Optica Spectrum Disorders

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Second Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Guangdong 999 Brain Hospital

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Wei Qiu · Third Affiliated Hospital, Sun Yat-Sen University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-21
Primary Completion
2020-01-02
Completion
2020-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04101058 on ClinicalTrials.gov